Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial
Artikel-Kategorie: Research Article
Online veröffentlicht: 17. Feb. 2023
Seitenbereich: 70 - 79
Eingereicht: 03. Okt. 2022
Akzeptiert: 08. Nov. 2022
DOI: https://doi.org/10.2478/raon-2023-0001
Schlüsselwörter
© 2023 Zhongxing Shi, Dongqing Wang, Tanrong Kang, Ru Yi, Liming Cui, Huijie Jiang, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Background
This trial aimed to compare the outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres® microspheres (CSM) and conventional transarterial chemoembolization cTACE in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Patients and methods
A total of 90 patients were divided into DEB-TACE group (n = 45) and cTACE group (n = 45). The treatment response, overall survival (OS), progression-free survival (PFS), and the safety were compared between the two groups.
Results
The objective response rate (ORR) in the DEB-TACE group was significantly higher than that in cTACE group at 1, 3, and 6 months of follow-up (
Conclusions
DEB-TACE with CSM showed better treatment response and survival benefits than cTACE group. Although a transient more severe liver damage, high incidence of fever and a severe abdominal pain occurred in the DEB-TACE group, it could be resolved through symptomatic treatment.